Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Authorization could allow Nuvaxovid™ to be used as a booster regardless of previous vaccine history GAITHERSBURG, Md., Sept. 1, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious…

Click here to view original post